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Apopulation-based cytogenetic study of adults with acute lymphoblastic leukemia
Anthony V. Moorman,1 Lucy Chilton,1 Jennifer Wilkinson,2 Hannah M. Ensor,1 Nick Bown,3 and Stephen J. Proctor2
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne; 2Department of Haematology, Royal Victoria Inﬁrmary, Newcastle upon
Tyne; and 3National Health Service Northern Genetics Service, Newcastle upon Tyne, United Kingdom
Chromosomal abnormalities are increas-
ingly used to risk stratify adults with
acute lymphoblastic leukemia. Published
data describing the age-speciﬁc inci-
dence of chromosomal abnormalities and
their prognostic relevance are largely de-
rived from clinical trials. Trials frequently
have age restrictions and low recruitment
rates. Thus we investigated these factors
in a population-based cohort of 349 pa-
tients diagnosed during the course of
19 years in the northern part of England.
The incidence of most chromosomal ab-
normalities varied signiﬁcantly with age.
The incidence of t(9;22)(q34;q11) in-
creased in each successive decade, up to
24% among 40- to 49-year-old subjects.
Thereafter the incidence reached a
plateau. t(4;11)(q21;q23) and t(1;19)(q23;
p13) were a rare occurrence among pa-
tients older than 60 years of age. In con-
trast, the frequency of t(8;14)(q24;q32)
and t(14;18)(q32;q21) increased with age.
High hyperdiploidy occurred in 13% of
patients younger than 20 years of age but
in only 5% of older patients. The inci-
dence of low hypodiploidy/near-triploidy
and complex karyotype increased with
age from 4% (15-29 years) to 16%
(> 60 years). Overall survival varied sig-
niﬁcantly by age and cytogenetics. Older
patients and those with t(9;22), t(4;11),
low hypodiploidy/near-triploidy, or
complex karyotype had a signiﬁcantly in-
ferior outcome. These population-based
results demonstrate the cytogenetic het-
erogeneity of adult acute lymphoblastic
leukemia. These data will inform the de-
livery of routine clinical services and the
design of new age-focused clinical trials.
(Blood. 2010;115:206-214)
Introduction
Recurrent and clonal chromosomal abnormalities in the leukemic
cells of patients with acute lymphoblastic leukemia (ALL) are the
hallmark of the disease and are now routinely used in the pediatric
setting to assist patient management, particularly in terms of
diagnosis, disease monitoring, prognosis, and risk stratiﬁcation.1
The clinical utility of cytogenetics in adult ALL is an emerging
topic, and more studies are urgently required.2,3 To date the
majority of cytogenetic studies (pediatric and adult) have been
based on patients enrolled in local, national, or international
clinical trials. In pediatric ALL these studies can be considered
representative because recruitment rates in this age group are very
high. However, trial recruitment is much lower among adolescents
and adults.4 Moreover, adults older than 60 years of age are rarely
eligible for clinical trials.5,6
Population-based studies of adult ALL are rare. The lack of
studies describing the age-speciﬁc incidence of chromosomal
abnormalities and their prognostic relevance makes planning the
delivery of routine clinical care services and clinical trials difﬁcult.
There are several current issues that would beneﬁt signiﬁcantly
from such data. First, the treatment of adolescents and young adults
is controversial, with many clinical trial groups opting to treat them
with the use of pediatric protocols.7-10 However, the distinct genetic
proﬁle of these patients has not been taken into consideration.11
Second, there is renewed interest in developing treatment protocols
for older (ie,  60 years) adults.12 Finally, the authors of recent
studies2,3 have demonstrated that cytogenetics is highly predictive
of outcome in adultALL, but the effectiveness of these markers has
not been tested outside clinical trials. In this report we present
population-based cytogenetic, clinical, and outcome data from
349 adult ALL patients diagnosed during a 19-year period in a
single region in the northern part of England.
Methods
Study area and population data
The study area comprised the region served by the National Health Service
(NHS) North East Strategic Health Authority during this period. The total
population of this region is 3.1 million and includes 2.5 million people ages
15 years or older (Ofﬁce for National Statistics; http://www.statistics.gov.uk/).
Age-speciﬁc incidence rates were calculated by the use of the average of the
population determined by the 1991 and 2001 United Kingdom censuses (Ofﬁce
for National Statistics). Since October 1982, the consultant hematologists in this
region have collaborated to keep a register of all newly diagnosed patients with
ALL.5 Ethical approval to conduct this audit was granted by the institutional
review boards of all relevant treatment centers.
Diagnosis
All patients diagnosed with ALL between January 1, 1983, and December,
31, 2001, who were 15 years or older were included in this study. In all
cases, the diagnosis was conﬁrmed by morphology and appropriate
cytochemical staining. Immunophenotyping was performed where possible
by the use of standard methodologies, and cases were retrospectively
classiﬁed into 1 of 5 subgroups (pro-B, B-cell precursor ALL, mature-B,
T-lineage [T]-ALL, and biphenotypic) by the use of the original immuno-
logic classiﬁcation.
Cytogenetics
Cytogenetic studies were performed at 1 of 3 laboratories in the region (see
Acknowledgments) but collated by the NHS Northern Genetics Service.
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samples by the use of standard G-banding techniques. Screening for the
major chromosomal translocations, ie, t(9;22)/BCR-ABL1, MLL/11q23
rearrangements, by the use of ﬂuorescence in situ hybridization (FISH)
and/or reverse-transcriptase polymerase chain reaction (RT-PCR) assays
became routine practice at the beginning of 1997. Chromosomal abnormali-
ties were deﬁned and recorded according to the International System for
Human Cytogenetic Nomenclature.13 None of the patients presented in this
report was included in the previous cytogenetic study of patients treated on
Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncol-
ogy Group (ECOG) 2993.2
Treatment
Patients younger than 55 years of age with ALL (B-cell precursor, T-cell,
and mature-B) or acute biphenotypic leukemia who were treated with
curative intent were mostly treated according to regional North East ALL
protocols (NE-ALL III-VI).14,15 Occasionally, patients were treated accord-
ing to, but not registered on, national protocols (UKALLXII,
UKALLXA).16,17 Acute biphenotypic leukemia was deﬁned as terminal
deoxynucleotidyl transferase (TdT)–positive patients who also expressed
some myeloid antigens. In this era TdT positivity was considered the key
marker indicating involvement of the lymphoid lineage and hence ALL
therapy. The multiagent protocol NE-ALLIII15 was introduced in 1982 and
correlates with the start of this study. In 1984, routine standard maintenance
was discontinued for patients younger than 55 years of age and instead
these patients were offered, in ﬁrst remission, an allogeneic transplant or, in
the absence of a family donor, an autologous transplant.14 Patients younger
than45 yearsofageunderwentapreconditioningregimenofcyclophospha-
mide (60 mg/kg) and total-body irradiation (1200 cGy), and those aged
45 to 55 years received melphalan (3 mg/kg), total-body irradiation
(1050 cGy), and noncryopreserved marrow rescue.
Between 1988 and 1994 (NE-ALLIV-V), the use of idarubicin replaced
doxorubicin in induction because of improved penetration into the central
nervous system, and prednisolone was replaced by dexamethasone. Cranial
irradiation was used throughout NE-ALL III-V unless the patient received
irradiation as part of his or her conditioning for a transplantation. The last
NE-ALL protocol in the series, NE-ALL VI, started in 1994. Cranial
irradiation was abandoned and replaced by a consolidation phase, in which
2 courses of high-dose methotrexate were alternated with 2 courses of
high-dose iphosphamide, epirubicin, and etoposide. The transplant policy
in NE-ALLVI was the same as NE-ALLIV-V and was applied consistently
until 2001. Patients aged 55 years or older were treated as previously
described.5
Statistics
Categorical variables were compared by the use of the 2 or Fisher exact
tests.The Mann-Whitney rank test was used to compare the age distribution
of different cytogenetic subgroups. Complete remission (CR) was deﬁned
morphologically as fewer than 5% blasts in the bone marrow, immunologi-
cally as TdT/CD10 negativity (before 1995), or by molecular assessment of
immunoglobulin and T-cell gene rearrangements (after 1995). Survival
analysiswasrestrictedtothosepatientswhoweretreatedbyanintention-to-
cure protocol (n  250). Patients who received only palliative care, those
who presented with advanced organ failure, and those who died before a CR
could be assessed were deemed not to have received treatment with curative
intent (n  99) and, therefore, were not included in the survival analysis.
Overall survival (OS) was deﬁned as the time from diagnosis to death or
last contact. Survival estimates, life tables, and curves were constructed
using the Kaplan-Meier method. The variables age and cytogenetic risk
group initially were analyzed in isolation by the use of univariate Cox
regression models. Multivariate Cox regression on these variables was then
performed via a stepwise modeling process on the basis of the difference
between successive models calculated by use of the log likelihood. At this
stage of analysis there was a further reduction of the number of patients
analyzed as the result of missing cytogenetics (n  73), dates (n  13), or
because of statistical concerns over their excessive inﬂuence on the model
(n  2). Thus a total of 162 patients were included in the multivariate
model. Because of the exploratory nature of this analysis, all calculations
were considered at the 5% signiﬁcance level.
Results
Descriptive epidemiology
A total of 349 adults aged 15 years or older were diagnosed with
ALL during the study period. Although the number of patients
diagnosed each year varied, there was no trend toward either an
increase or decrease in the incidence of the disease during the study
period (Figure 1). The incidence of ALL varied by age, and a
bimodal distribution was observed, with the younger (15-19 years
old) and older ( 70 years) adults having the greatest incidence
(Figure 2). Approximately one-third of the patients were 60 years
or older (Table 1).
Overall there were more male than female subjects (1.2:1 M:F),
but this ratio varied signiﬁcantly with age (P  .03;Table 1; Figure
2). The excess of male patients was conﬁned to younger adults,
where the ratio was 1.8:1 M:F. In addition, the excess of male
patients was more pronounced among T-ALL patients, where a
ratio of 2.2:1 M:F was observed.T-ALLpatients were also younger
(see next paragraph). Figure 2 shows the age-speciﬁc incidence of
ALL for male and female patients separately, demonstrating that
the change in the sex ratio with increasing age is not simply a
function of the increased life expectancy enjoyed by females.
The majority of patients had a B-lineage ALL (240, 81%),
whereas 42 (14%) had T-ALL and 15 (5%) were described as
biphenotypic (see “Methods”). However, this distribution differed
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Figure 1. Number of patients diagnosed in the north-
ern part of England with adult ALL between 1983 and
2001 subdivided by cytogenetic analysis at diagno-
sis.
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ALL, which comprised 11% of patients overall, were signiﬁcantly
older, with a median age of 63 years (interquartile range [IQR],
53-71 years) versus 42 years (IQR, 23-66 years; P  .001). In
contrast, T-ALLpatients were signiﬁcantly younger, with a median
age of 25 years (IQR, 19-42 years) versus 48 years (IQR, 26-
69 years; P  .001).
White cell count (WCC) was strongly correlated with immuno-
phenotype. Patients with T-ALL were signiﬁcantly more likely to
have a WCC of greater than 50  109/L compared with B-lineage
patients: 17 (40%) of 42 versus 47 (19%) of 247 (P  .001). Given
that patients with T-ALL were also signiﬁcantly younger (see
previous paragraph), this ﬁnding translated into older patients
appearing to have a lower WCC (Table 1). However, no such
effect was observed if the T-ALL patients were excluded (data
not shown).
Diagnostic cytogenetic analysis
Cytogenetic analysis was attempted in 292 (84%) of 349 patients
but was signiﬁcantly more prevalent after 1993: 160 (94%) of
171 versus 132 (74%) of 178 (P  .001; Table 1; Figure 1). This
ﬁnding was true across all age groups (data not shown). A total of
236 (81%) of 292 had a successful cytogenetic result, and a clonal
chromosomal abnormality was detected in 174 (74%) of 236 pa-
tients. These rates did not vary during the study period (P  .05) or
by age (P  .05). Overall cytogenetics revealed a normal karyo-
type in 63 (27%) patients, but this ﬁnding was more prevalent
among T-ALL patients (14/30, 47%) compared with B-lineage
patients (38/176, 22%; P  .006). Because T-ALL patients are
younger, this explains the greater incidence of normal karyotype in
adolescents (15-19 years).
The most prevalent speciﬁc chromosomal abnormality was the
Philadelphia chromosome, t(9;22)(q34;q11), BCR-ABL1, which
was present in 36 (15%) of 236 patients. There was no difference in the
incidence before and after the introduction of routine FISH/RT-PCR at
the beginning of 1997: 24 (15%) of 158 versus 12 (13%) of
92 (P  .1). The prevalence increased with age up to, but not
beyond, the fourth decade: 15 to 19 years, 2 (5%) of 42; 20 to
29 years, 4 (11%) of 35; 30 to 39 years 4 (15%) of 26; 40 to
49 years, 7 (24%) of 29; 50 to 59 years 5 (21%) of 24; 60 to
69 years, 8 (21%) of 38; 70 to 79 years, 4 (13%) of 30; 80 years or
older, 2 (17%) of 12. Thus, although there was a signiﬁcant
difference in the incidence of t(9;22) between patients ages 15 and
30 years (7%) and those older than 30 years of age (24%; P  .02),
there was no difference between those ages 30 to 60 years (22%)
and older than 60 years of age (16%; P  .4). The majority of
t(9;22) patients had B-cell precursor–ALL (32/35, 91%) but
3 patients were described as having a biphenotypic immunopheno-
type. Just more than one-half the t(9;22) patients (19/34, 56%) had
a WCC less than 50  109/L, whereas the remaining 15 patients
had a WCC of more than 50  109/L, including 10 patients with a
WCC of more than 100  109/L.
Other established chromosomal translocations, such as t(4;11),
t(1;19), t(8;14), and t(14;18), each occurred in less than 10% of
patients but showed strong correlations with age. Both t(4;11) and
t(1;19) occurred more often in younger adults and t(8;14) and
t(14;18) in older adults ( 60 years; Table 2). The 2 ploidy
subgroups, high hyperdiploidy (51-65 chromosomes, HeH) and
low hypodiploidy/near triploidy (30-39 and 60-78 chromosomes,
HoTr), were observed in 7% and 3% of patients, respectively. None
of these patients had T-ALL or mature-B ALL, and they were
associated with younger and older age, respectively (Table 2).
Patients without one of the aforementioned established chromo-
somal abnormalities or tetraploidy were classiﬁed as having a
complex karyotype if 5 or more clonal chromosomal abnormalities
were observed. This subgroup accounted for 7% of patients overall
but was more prevalent among patients older than 60 years of age.
Collectively, Philadelphia-negative patients with high-risk cytoge-
netics, deﬁned as t(4;11), t(8;14), HoTr, and complex karyotype,2
were signiﬁcantly more prevalent among patients older than
60 years of age: 24 (36%) of 66 versus 25 (19%) of 134 (P  .006).
The most prevalent cytogenetic subgroups were the other
abnormal group and those with a normal karyotype, which together
accountedformorethan50%ofpatientswithsuccessfulcytogenet-
ics. Among the 59 patients classiﬁed as “other abnormal,” some
known chromosomal abnormalities were observed but were too
infrequent to be analyzed separately. Examples included t(10;
14)(q24;q11),n  2,andt(11;14)(p13;q11),n  1.Knownsecond-
ary chromosomal abnormalities, such as deletions of 6q (n  9)
and 9p (n  6), also were observed both in combination with
established abnormalities and within the “other abnormal” and
complex karyotype groups but at too low a frequency to be
analyzed separately.
Outcome and prognostic relevance of chromosomal
abnormalities
Among the 349 patients in this cohort, 250 (72%) were treated with
curative intent. This number included 211 (94%) of 225 patients
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Figure 2. Age-speciﬁc incidence of adults withALLin
the northern part of England by sex.
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older than 60 years of age. Only the outcome of patients who were
actively treated has been considered in this section. CR was
achieved in 194 (78%) of 247 patients who were actively treated.
However, this rate varied by age and cytogenetics (Tables 1-2).
Signiﬁcantly fewer patients older than 60 years of age achieved a
CR compared with those younger than 60 years: 20 (51%) of
39 versus 174 (84%) of 208 (P  .001). In addition, fewer
patients with t(9;22) or other high-risk cytogenetics achieved a
CR (Tables 1-2).
Among the 250 actively treated patients, 100 (40%) received an
autologous (n  66), allogeneic (n  29), or matched unrelated
donor (n  6) bone marrow transplant. All but 6 of the transplants
were performed in ﬁrst CR. None of the patients older than
60 years of age received a transplant, compared with 59 (51%)
of 115 patients 15 to 29 years old and 41 (37%) of 110 patients
30 to 60 years old. The remaining 99 patients received chemo-
therapy alone.
Given the duration of the study and the heterogeneity of
treatments received, we have only considered OS. Recent data
Table 1. Demographic, clinical, and cytogenetic features of 349 adults with ALL
Age, y
Total 15 to 29 30 to 59 60 or older
No. of patients 115 110 124 349
Sex ratio, M:F 1:0.6 1:1.1 1:1.1 1:0.9
WCC  109/L, n (%)*
 10 55 (48) 40 (38) 42 (41) 137 (43)
10-49.9 35 (30) 33 (32) 46 (45) 114 (36)
 50 24 (21) 31 (30) 14 (14) 69 (21)
Immunophenotype, n (%)†
Pro-B 7 (7) 15 (15) 11 (12) 33 (10)
B-cell precursor 71 (68) 60 (59) 44 (49) 175 (55)
Mature B 1 ( 1) 10 (10) 21 (23) 32 (10)
T-ALL 26 (25) 11 (11) 5 (6) 42 (13)
Biphenotypic 0 6 (6) 9 (10) 15 (5)
Cytogenetic investigations
Attempted 98 (85) 100 (91) 94 (73) 292 (84)
Successful 77 (79) 79 (79) 80 (85) 236 (81)
Normal 25 (32) 19 (24) 18 (23) 62 (26)
Abnormal 52 (68) 60 (76) 62 (77) 174 (74)
Cytogenetic investigations before January 1993, n (%)
Attempted 44 (76) 51 (86) 37 (61) 132 (74)
Successful 32 (73) 38 (75) 30 (81) 100 (76)
Normal 12 (38) 8 (21) 11 (37) 31 (31)
Abnormal 20 (63) 30 (79) 19 (63) 69 (69)
Cytogenetic investigations after January 1993, n (%)
Attempted 54 (95) 49 (96) 57 (90) 160 (94)
Successful 45 (88) 41 (84) 50 (88) 136 (85)
Normal 13 (29) 11 (27) 7 (14) 31 (23)
Abnormal 32 (71) 30 (73) 43 (86) 105 (77)
Chromosomal abnormality, n (%)‡
Total 77 79 80 236
t(9;22)(q34;q11) 6 (8) 16 (20) 14 (18) 36 (15)
t(4;11)(q21;q23) 4 (5) 5 (6) 1 (1) 10 (4)
t(1;19)(q23;p13) 4 (5) 2 (3) 0 6 (3)
t(8;14)(q24;q32) 0 7 (9) 10 (13) 17 (7)
t(14;18)(q32;q21)§ 0 2 (3) 8 (10) 10 (4)
HeH 10 (13) 4 (5) 3 (4) 17 (7)
HoTr¶ 1 (1) 2 (3) 4 (5) 7 (3)
Complex# 2 (3) 4 (6) 9 (11) 15 (7)
Other 25 (32) 18 (23) 16 (20) 59 (25)
Normal** 25 (32) 19 (24) 18 (23) 62 (26)
CR rate, % (n)†† 89 (99/111) 77 (75/97) 51 (20/39) 79 (194/247)
OS estimate, 5 y (95% conﬁdence interval), %‡‡ 45 (35-55) 19 (11-28) 12 (4-27) 30 (24-36)
ALL indicates acute lymphoblastic leukemia; CR, complete remission; HeH, high hyperdiploidy; HoTr, low hypodiploidy/near triploidy; OS, overall survival;T-ALL,T-lineage
acute lymphoblastic leukemia; and WCC, white cell count.
*Information only available for 320 patients.
†Information only available for 297 patients.
‡Mutually exclusive.
§This chromosomal abnormality was expressed in conjunction with the t(8;14) in 3 patients.
High hyperdiploidy (51-65 chromosomes).
¶Low hyperdiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes).
#Complex karyotype deﬁned as 5 or more chromosomal abnormalities in the absence of an established cytogenetic subgroup.
**Atotal of 20 or more normal metaphases in the absence of any clonal chromosomal abnormality.
††CR only available for 247 patients.
‡‡OS rate available for 234 patients as the result of missing data.
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poor18; hence this is a suitable end point to be considered by this
study. The median follow-up time for this cohort was 6.25 years.
The 5-year OS rate for the whole cohort was 30% (95% conﬁdence
interval [CI], 24%-36%). However, this ﬁgure varied considerably
by age and cytogenetics (Tables 1-2; Figures 3-4). Estimates of the
5-year OS rates by each decade were as follows: 15 to 19 years,
47% (95% CI, 33%-61%); 20 to 29 years, 43% (95% CI, 29%-
57%); 30 to 39 years, 16% (95% CI, 6%-32%); 40 to 49 years, 20%
(95% CI, 8%-36%); 50 to 59 years, 19% (95% CI, 7%-36%);
60 years or older, 12% (3%-27%).
Older patients and those with poor-risk cytogenetics, as deﬁned
by the MRC UKALLXII/ECOG 2993 trial, had a signiﬁcantly
worse outcome (Tables 1-2; Figures 3-4). We have already
demonstrated (Tables 1-2) that cytogenetics and age are closely
related. The frequency of poor-risk cytogenetics, for example,
t(9;22), t(8;14), HoTr, and complex karyotype, was greater among
older patients, and fewer older patients had HeH. Little change was
noted in the outcome of patients during the study period.Although
there was a marginally increase in the OS at 5 years for patients
ages 30 years and older, the difference was not statistically
signiﬁcant (data not shown).
To determine whether the adverse affect of cytogenetics was
independent of age we performed multivariate analysis. Because of
the relatively small number of patients with both cytogenetic and
outcome data (n  162), we were able to consider only 3 cytoge-
netic risk groups: t(9;22), all patients with t(9;22)/BCR-ABL; poor,
patients with t(4;11), t(8;14), t(14;18), HoTr, and complex karyotype;
and standard, all other patients. A Cox proportional hazards model
containing just age and cytogenetic risk group indicated a statistical
interaction between age and cytogenetics. When we added an interac-
tion term to the model, it revealed that both age and cytogenetics were
contributing signiﬁcantly to outcome. Patients with t(9;22) had a
12.5-foldincreaseriskofdying(hazardratio12.50,95%CI,2.69-58.07,
P.001) whereas those with poor-risk cytogenetics had a 3.5-fold
increased risk (hazard ratio 3.47, 95% CI, 1.45-8.37, P  .007),
both in comparison with patients with standard-risk cytogenetics.
The statistical interaction between cytogenetics and age indicates
Figure 3. OS of adults withALL by age at diagnosis.
Table 2. Demographic, clinical, and survival data for 349 adults with ALL
Total, n
(%) Sex ratio, M/F
Age WCC*
Outcome†
Treated, n
(%)
CR rate,
n (%)‡ Deaths, n (%)§
OS at 5 years
Mean
Older than
60 y, % Median
More than
50, % OS, % 95% CI, %
Total (full dataset) 349 1:0.9 46.4 36 13.6 20 250 (72) 194 (70) 177 (73) 30 (24- 36)
Successful cytogenetics
Total 236 1:0.8 45.4 34 14.6 20 177 (75) 133 (75) 126 (71) 29 (22- 37)
t(9;22)(q34;q11) 36 (15) 1:0.6 50.6 39 30.1 42 26 (72) 17 (65) 24 (92) 9 (2- 26)
t(4;11)(q21;q23) 10 (4) 1:1.5 39.1 10 43.6 50 9 (90) 7 (78) 6 (67) 33 (at
3 years)
(8-62)
t(1;19)(q23;p13) 6 (3) 1:5 33.2 21.5 16 6 (100) 6 (100) 3 (50) 60 (13- 88)
t(8;14)(q24;q32) 17 (7) 1:0.9 60.8 59 15.7 6 10 (59) 4 (44) 8 (80) 20 (3%- 48%)
t(14;18)(q32;q21)¶ 10 (4) 1:0.8 60.0 67 20.0 16 5 (50) 2 (40) 4 (80) 33 (at
1 year)
(1-77)
HeH# 17 (7) 1:0.5 33.9 18 3.1 6 15 (88) 15 (100) 5 (36) 77 (45-92)
HoTr‡‡ 7 (3) 1:1.3 55.1 86 2.6 — 6 (86) 4 (67) 6 (100) 0 —
Complex†† 15 (7) 1:0.5 58.9 60 13.0 — 5 (33) 4 (80) 4 (80) 20 (1- 58)
Other 59 (25) 1:0.8 42.2 29 16.3 24 48 (85) 39 (81) 34 (76) 27 (14-41)
Normal‡‡ 62 (26) 1:0.7 40.8 29 10.0 16 49 (79) 35 (71) 34 (69) 32 (18-46)
Cytogenetic risk group
t(9;22) 36 (15) 1:0.6 50.6 39 30.1 42 26 (72) 17 (65) 24 92% 9 (2-26)
Poor 56 (24) 1:1.3 55.8 52 15.2 13 33 (59) 21 (66) 26 79% 19 (7-36)
Standard 144 (61) 1:0.8 40.0 26 11.0 18 118 (82) 95 (82) 76 67% 37 (27-46)
ALL indicates acute lymphoblastic leukemia; CI, conﬁdence interval; CR, complete remission; HeH, high hyperdiploidy; HoTr, low hypodiploidy/near triploidy; OS, overall
survival; and WCC, white cell count.
*Information only available for 320 patients.
†This only includes those 250 patients treated with curative intent.
‡CR only available for 247 patients.
§Status unavailable for 16 patients.
OS information available for 234 patients as the result of missing data.
¶This chromosomal abnormality was expressed in conjunction with the t(8;14) in 3 patients
#High hyperdiploidy (51-65 chromosomes).
‡‡Low hyperdiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes).
††Complex karyotype deﬁned as 5 or more chromosomal abnormalities in the absence of an established cytogenetic subgroup.
‡‡Atotal of 20 or more normal metaphases in the absence of any clonal chromosomal abnormality.
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However, given the size of the cohort, the relatively crude measure
of outcome used, and the heterogeneity of treatment, it was not
possible to investigate this further.
Incidence of major chromosomal abnormalities in this study
compared with previously published data from clinical trials
We compared the incidence of the major chromosomal abnormali-
ties in this study to that observed in 6 major clinical trials (Table 3).
Because researchers of most clinical trials impose age limits on
potential subjects, we restricted the comparison with those patients
in this study between 15 and 59 years of age. Aside from the
variation in the incidence of normal karyotype and t(9;22) there
was little difference. However, it should be noted that several of the
abnormalities were only classiﬁed in a few studies. The overall
frequency of t(9;22) in this population-based study was 15%,
which compares well with that reported by the 2 recent United
Kingdom–based trials: MRC UKALLXA(11%)17 and UKALLXII
(16%).2 In contrast, the overall frequency of t(9;22) ALL reported
by other trial based studies is much greater: ECOG2993 (25%),2
GMALL (36%),19 GIMEMA0496 (23%-31%),20 GFCH (29%),21
SWOG9400 (27%),3 and CALGB (26%)22 (Table 4). These
differences are likely to be attributable to a combination of factors,
including the age proﬁle of the underlying populations, recruitment
bias, and detection method. Although there are exceptions, gener-
ally studies with a lower frequency of t(9;22) comprise a greater
proportion of younger patients and vice versa.
Discussion
We have reported the largest population-based cytogenetic study of
adults withALL. The overall incidence rate and pattern of incidence by
age and sex was similar to that observed in other areas of the United
Kingdom.23 This was an appropriate region in which to examine the
relationship between age and cytogenetics. First, there was no overlap
with the previous publication on the basis of the MRC UKALLXII/
ECOG 2993 cohort from which we derived our cytogenetic risk criteria.
Although some patients (10%) were treated according to the same
protocol, they were not ofﬁcially registered on the trial. Second, the
age-speciﬁc OS rates observed in this region were similar to that
observed in other regions of the United Kingdom.4,24 The results clearly
demonstrate that the incidence of cytogenetic and immunophenotypic
subgroups varies markedly with the age. Although it is known that the
incidence of speciﬁc chromosomal abnormalities differs between chil-
dren and adults, the age-speciﬁc frequency of such lesions within adult
ALL, especially among those older than 60 years of age, was hitherto
unknown or poorly studied.
The results of recent clinical trials of adult ALL have high-
lighted the importance of cytogenetics in predicting the risk of
relapse.2,3 Such studies support the development of cytogenetic-
based risk stratiﬁcation of adults in future trials. One of the
limitations of these studies was that they were based on a relatively
small proportion of the total available patients because most adult
patients withALLare not recruited to clinical trials. One of the key
questions in this ﬁeld of research is whether the speciﬁc chromo-
somal abnormalities identiﬁed as being indicators of poor outcome
in the MRC UKALLXII/ECOG2993 trial retained their prognostic
relevance outside the context of a clinical trial. Our analyses
suggest that both age and cytogenetics are important predictors of
outcome in adultALL.The relatively small number of patients with
individual poor-risk chromosomal abnormalities prevented an
in-depth analysis. Overall the data in this study support our
previous observations that patients with t(4;11), t(8;14), HoTr, and
complex karyotype have an inferior outcome. However, it should
be noted that (1) there was evidence to suggest that the effect of
cytogenetics varied with age, and (2) the treatment received by this
cohort was during a 19-year period and hence heterogeneous.
Figure 4. OS of adults withALL by cytogenetic risk group.
Table 3. Incidence of major chromosomal abnormalities in adult ALL observed in this study compared with previously
published clinical trials
Study Reference Patients tested, n t(9;22) % t(4;11) % t(1;19) % t(8;14) % t(14;18) % HeH, %* HoTr, %†
Complex,
%‡
Normal,
%§
This study (15- to 59-year-old
patients only)
NA 236 15 6 4 4 1 9 2 4 29
MRC UKALLXA 17 350 11 3 3 NA NA 8 NA NA 34
UKALLXII/ECOG2993 2 1373 19 4 2 1 NA 6 2 3 14
CALGB 22 256 26 5 NA NA NA NA NA NA 25
GIMEMA 0496 20 386 26 7 2 NA NA NA NA NA 26
SWOG 9400 3 140 26 5 5 NA NA NA NA NA 22
GFCH 21 443 29 4 3 5 NA 7 NA NA 15
ALL indicates acute lymphoblastic leukemia; CALGB, Cancer and Leukemia Group B; GFCH, Français de Cytogénétique Hématologique; GIMEMA, Gruppo Italiano
Malattie Ematologiche Ddell’Adulto; HeH, high hyperdiploidy; HoTr, low hypodiploidy/near triploidy; MRC, Medical Research Council; NA, not available; SWOG, Southwest
Oncology Group.
*High hyperdiploidy (51-65 chromosomes).
†Low hyperdiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes).
‡Complex karyotype deﬁned as 5 or more chromosomal abnormalities in the absence of an established cytogenetic subgroup.
§Atotal of 20 or more normal metaphases in the absence of any clonal chromosomal abnormality.
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that the frequency of t(9;22)/BCR-ABL–positive adult ALL does
not continue to increase beyond the fourth decade of life. These
results are in contrast to the popularly held belief that the incidence
of t(9;22)-positiveALL continues to increase with age. The overall
frequency of t(9;22) ALL in this study and other United Kingdom
trial studies was considerably lower than that observed in series
from other countries (Table 4). Although differences in the age
proﬁle of the underlying populations are likely to explain some of
the variation, the picture appears more complicated and may reﬂect
geographical heterogeneity.25 Patients with t(9;22) now usually are
treated with imatinib mesylate or another tyrosine kinase inhibitor
in combination with multiagent chemotherapy. These data indicate
that such therapy will be suitable for a smaller fraction of patients
older than 60 years of age than had been anticipated.
Although this study is the largest and most comprehensive of its
kind to date, it does have limitations. First, the number of patients
was still quite small, and hence, the number with speciﬁc chromo-
somal abnormalities was too few to undertake detailed survival
analysis. Second, rarer and secondary chromosomal abnormalities
could not be considered. Third, although most treatment occurred
in a single center and with the same ethos, this study spanned
nearly 20 years. Finally, the global genomic analysis of childhood
ALL has revealed a wide spectrum of copy number alterations
beyond the resolution of cytogenetics.26 Many are microdeletions
targeting B-cell development genes (eg, IKZF1, PAX5, VpreB1),
and most correlate with established cytogenetic subgroups.26,27
Initial investigations in adult ALL by Paulsson et al28 suggest that
similar copy number alterations are present. Given that approxi-
matelyone-halfofthepatientsinthisstudycouldnotbeassignedto
a clinically relevant cytogenetic subgroup, future studies will need
to incorporate high-quality cytogenetic, FISH and genomic data to
fully characterize patients. Moreover, such studies will need to be
population based to efﬁciently plan services, design clinical trials,
and fully use the prognostic relevance of genetic markers.
The authors of several recent studies7-10 have reported that
adolescents and young adults (AYAs) have a better outcome when
treated with pediatric protocols. Several groups worldwide10,29 are
now treating AYAs up to the age of 29 years with the use of
pediatric protocols. BecauseAYAs are much less likely to enroll in
clinical trials than children,4 this study is the most informative to
date as to their cytogenetic proﬁle. Interestingly it is markedly
different from both the classical pediatric proﬁle and the adult
proﬁle.1The frequency of HeH is much lower than observed among
childhood cohorts (13% vs  30%), whereas the frequency of
t(9;22) and other “adult” cytogenetic abnormalities such as HoTr
and complex karyotype is much lower. Unfortunately, our patients
have not been screened for ETV6-RUNX1 fusion. However, our
previous study30 suggested that this would be present at a much
lower frequency than in childhood ALL. The frequency of T-ALL
is this age group is noteworthy; at 25%, it is greater than in both
childhoodALLand adults aged older than 30 years of age.
One of the major strengths of this study is the unselected nature of
thecohort,andwewereabletoestimatetheincidenceofALLatallages,
and by sex and year of diagnosis. There was no evidence to suggest that
the incidence of this disease was increasing with time. However, the
observation that the incidence continues to increase with age among
both male and female patients suggests that the absolute number of
patients is likely to increase in the context of an aging population. Thus
“elderly” ALL is likely to become an increasing health burden during
the next 2 decades, especially as other authors6 have reported that there
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clinical trials targeting this age group are urgently required.
We were able to examine the cytogenetic proﬁle of 124 patients
older than 60 years of age. This age group is largely underreported
because the upper age limit of most clinical trials is 55 to 65 years.
Although diagnostic cytogenetic investigations were less fre-
quently requested in this age group, when they were attempted the
success and abnormality rates were similar, if not better, compared
with younger patients. These results suggest that pretreatment
cytogenetic analysis for adults with ALL should be performed
irrespective of age. Interestingly the biologic and cytogenetic
proﬁle of these “older” patients was quite different compared with
younger patients. Mature-B ALL, plus t(8;14)/t(14;18), was more
prevalent, whereas T-ALL was markedly less prevalent. Such
information is important for planning the delivery of routine
clinical care services and designing clinical trials. Patients with
mature-B ALL will now routinely receive treatment on lymphoma
protocols.31 The translocations t(4;11) and t(1;19) were rare among
patients older than 60 years of age, as was HeH. In contrast, the
recently established poor-risk groups—HoTr and complex karyo-
type—were more prevalent in this older subgroup.
Because older adults ( 60 years) were less likely to receive
curative treatment, the proportion of such patients included in
the multivariate model was lower. Hence, it is difﬁcult to assess
the effect of cytogenetics in this age group. Recent data from the
Surveillance, Epidemiology and End Results Program showed
that this age group was the only one that has not beneﬁted from
recent improvements in survival.6 Therefore, further investiga-
tion into the cytogenetics of this age group is urgently required
to maximize the usefulness of future clinical trials aimed at this
age group.
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